Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.

Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement for younger adults with severe aortic stenosis rose nearly ninefold from ...

People with severe aortic stenosis, a condition where the heart’s aortic valve narrows and restricts blood flow, can already undergo a less invasive and faster procedure compared to traditional ...

RANCHO MIRAGE, Calif., Jan. 4, 2024 /PRNewswire/ -- Eisenhower Health is the first hospital in the United States to become an Edwards Benchmark program Case Observation Site for the treatment of ...

For the rising number of patients needing aortic reintervention, transcatheter aortic valve replacement (TAVR) explantation carried the highest mortality risk, two registry analyses affirmed. In ...

St. Luke’s Medical Center-Global City marks a significant milestone for its cardiovascular services, having successfully ...

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic valve stenosis. With proven safety and efficacy, TAVR has become a standard therapeutic alternative to surgical ...

Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis, many hospitals are still opting for a nonsurgical approach in ...

The Federal Trade Commission (FTC) has moved to block Edwards Lifesciences’ purchase of JenaValve Technology and its transcatheter heart valve implant for treating aortic regurgitation, which is ...